The Journal of the American Medical Association wants you to tell them about any potential undisclosed conflicts of interest by their authors – and then never mention it again (pdf).
The new policy forbids anyone from reporting potential conflicts to third parties and comes after a snippy exchange over a 2008 JAMA article on escitalopram that failed to report lecture fees paid by the drug’s manufacturers to one of the authors .
Dr. Jonathan Leo reported the potential conflict to JAMA, published his concerns in an article in BMJ, and reported it to the press. JAMA chastised Leo for going public and told The Wall Street Journal he was a nobody and a nothing. It suggested in an e-mail to Leo that his work would on longer be published in JAMA.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Effect Measure said JAMA has effectively made “sewage out of lemonade” by their actions. Dr. Roy M. Poses, writing on Health Care Renewal, calls the story and the new policy “saddening.”
We have probably favorably cited more editorials by JAMA on these topics than those in any other journal. Yet now the journal’s leadership seems to have somehow lost their way. Instead of trying to constructively respond to criticism, they now seem intent on punishing the critics. I hope they find their compass soon, before an important medical institution really is irreparably damaged.
More stories worth a read:
- MetroHealth Medical Center paid $10.2 million to CEO Mark Moran’s former firm (The Plain Dealer)
- Medical Students still favor specialties over primary care (Health Affairs)
- What happened to the nursing profession? (Happy Hospitalist)
- There’ll be No Follow-On Biologics in the US at All… (IN VIVO Blog)
- Michigan Growth Capital Symposium will welcome Canadian venture capital firms (Ann Arbor Business Review)
- Medical College of Wisconsin will cut its budget by 5 percent (Milwaukee Journal Sentinel)
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
[JAMA cover courtesy of the John P. McGovern Historical Collections and Research Center]
